Literature DB >> 26450273

Pronounced Inhibition Shift from HIV Reverse Transcriptase to Herpetic DNA Polymerases by Increasing the Flexibility of α-Carboxy Nucleoside Phosphonates.

Jubi John, Youngju Kim, Nicholas Bennett1, Kalyan Das2, Sandra Liekens, Lieve Naesens, Eddy Arnold2, Anita R Maguire3, Matthias Götte1, Wim Dehaen, Jan Balzarini.   

Abstract

Alpha-carboxynucleoside phosphonates-CNPs) are novel viral DNA polymerase inhibitors that do not need metabolic conversion for enzyme inhibition. The prototype contains a cyclopentyl linker between nucleobase and α-carboxyphosphonate and preferentially (50- to 100-fold) inhibits HIV-1 RT compared with herpetic DNA polymerases. A synthesis methodology involving three steps has been developed for the synthesis of a series of novel α-CNPs, including a Rh(II)-catalyzed O-H insertion that connects the carboxyphosphonate group to a linker moiety and an attachment of a nucleobase to the other end of the linker by a Mitsunobu reaction followed by final deprotection. Replacing the cyclopentyl moiety in the prototype α-CNPs by a more flexible entity results in a selectivity shift of ∼ 100-fold in favor of the herpetic DNA polymerases when compared to selectivity for HIV-1 RT. The nature of the kinetic interaction of the acyclic α-CNPs against the herpetic DNA polymerases differs from the nature of the nucleobase-specific kinetic interaction of the cyclopentyl α-CNPs against HIV RT.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26450273      PMCID: PMC4893804          DOI: 10.1021/acs.jmedchem.5b01180

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  29 in total

1.  Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.

Authors:  Christophe Vanpouille; Andrea Lisco; Andrea Introini; Jean-Charles Grivel; Arshi Munawwar; Melanie Merbah; Raymond F Schinazi; Marco Derudas; Christopher McGuigan; Jan Balzarini; Leonid Margolis
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

2.  Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Zhijun Zhang; Michelle Walker; Wen Xu; Jae Hoon Shim; Jean-Luc Girardet; Robert K Hamatake; Zhi Hong
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

3.  Phosphonoformic acid inhibits viral replication by trapping the closed form of the DNA polymerase.

Authors:  Karl E Zahn; Egor P Tchesnokov; Matthias Götte; Sylvie Doublié
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

4.  High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.

Authors:  Tara Perti; Misty Saracino; Jared M Baeten; Christine Johnston; Kurt Diem; Negusse Ocbamichael; Meei-Li Huang; Stacy Selke; Amalia Magaret; Lawrence Corey; Anna Wald
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

Review 5.  Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

Authors:  B Oberg
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

Review 6.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

7.  The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation.

Authors:  Moira A McMahon; Janet D Siliciano; Jun Lai; Jun O Liu; James T Stivers; Robert F Siliciano; Rahul M Kohli
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

Review 8.  Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance.

Authors:  Scott H James; Mark N Prichard
Journal:  Curr Opin Virol       Date:  2014-07-16       Impact factor: 7.090

Review 9.  Acyclic nucleosides as antiviral compounds.

Authors:  S Freeman; J M Gardiner
Journal:  Mol Biotechnol       Date:  1996-04       Impact factor: 2.695

Review 10.  Utility of the bacteriophage RB69 polymerase gp43 as a surrogate enzyme for herpesvirus orthologs.

Authors:  Nicholas Bennett; Matthias Götte
Journal:  Viruses       Date:  2013-01-08       Impact factor: 5.048

View more
  3 in total

Review 1.  Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance.

Authors:  Francesc Xavier Ruiz; Eddy Arnold
Journal:  Curr Opin Struct Biol       Date:  2020-01-11       Impact factor: 6.809

Review 2.  Alpha-carboxynucleoside phosphonates: direct-acting inhibitors of viral DNA polymerases.

Authors:  Jan Balzarini; Alan Ford; Nuala M Maguire; Jubi John; Kalyan Das; Eddy Arnold; Wim Dehaen; Anita Maguire
Journal:  Future Med Chem       Date:  2019-01-16       Impact factor: 3.808

Review 3.  Overview of Biologically Active Nucleoside Phosphonates.

Authors:  Elisabetta Groaz; Steven De Jonghe
Journal:  Front Chem       Date:  2021-01-08       Impact factor: 5.221

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.